Hainewalde, Germany

  • Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio

    The study will consist of a screening period, a treatment and assessment period and an End of Study visit. Eligibility for the study will be determined during a screening period. Subjects who meet the eligibility criteria will be randomised to either AVT16 or Entyvio.

    Phase

    3

    Span

    101 weeks

    Sponsor

    Alvotech Swiss AG

    Jaffna

    Recruiting

  • SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

    This study is a randomised, double blinded clinical trial and will be undertaken in primary care and community sites across Australia and tertiary care centres in Sri Lanka. Following a 4-week active run-in period, eligible participants will be randomised to either dapagliflozin 10mg daily, or metformin XR 2000mg daily in a 1:1 ratio.

    Phase

    3

    Span

    183 weeks

    Sponsor

    The George Institute

    Jaffna

    Recruiting

  • Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

    Intracerebral haemorrhage (ICH) is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur globally each year. Survivors of ICH are at high risk of recurrent ICH and other serious cardiovascular events. While there is strong evidence that this risk can be reduced by lowering the blood pressure (BP) of patients after ICH, many patients with ICH do not receive BP-lowering treatment long-term unless BP levels are particularly high, and many do not receive BP combination therapy. The aim of this study is to assess the safety and efficacy of a combination of fixed low-dose generic BP lowering agents, as a "Triple Pill" strategy on top of standard of care for the prevention of recurrent stroke in patients with a history of ICH and high normal or low grade hypertension. The study is a large-scale, international, double-blind, placebo-controlled, randomised controlled trial.

    Phase

    3

    Span

    405 weeks

    Sponsor

    The George Institute

    Jaffna

    Recruiting

1-3 of 3